Elvitegravir

Type: Keyphrase
Name: Elvitegravir
First reported Sep 16 2014 - Updated Sep 16 2014 - 2 reports

ICAAC 2014: Cobicistat Long-term Efficacy Matches Ritonavir as PI Booster

Details Category: Experimental HIV Drugs Published on Tuesday, 16 September 2014 00:00 Written by Liz HighleymanLong-term rates of viral suppression and side effects were among people using cobicistat and those using ritonavir as a booster for atazanavir ... [Published HIV and Hepatitis.com - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Subgroup Analysis of Response to Stribild vs Atripla or Atazanavir: 144 Weeks

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DC ICAAC: - (09/08/14) Mark MascoliniOverall response to Stribild generally matched responses ... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

First Single-Tablet PI Regimen With Darunavir and TAF at 48 Weeks

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DC ICAAC: - (09/08/14) Mark MascoliniCobicistat-boosted darunavir plus tenofovir alafenamide ... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Switch From RTV to COBI To Boost a PI With Moderate Kidney Impairment

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DC ICAAC: - (09/09/14) Mark MascoliniAmong people with moderate renal impairment (creatinine ... [Published National AIDS Treatment Advocacy Project - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

FDA Updates Stribild Labeling

On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two ... [Published AIDSinfo At-a-Glance: Offering Information on H ... - Sep 12 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 1 reports

Stribild Advantages vs Atripla in Blacks Through Trial Week 144

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC ICAAC 2014. September 5-9, 2014. Washington, DCFull poster report - ICAAC: - (09/08/14) Mark MascoliniPreviously untreated black study participants ... [Published National AIDS Treatment Advocacy Project - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 11 2014 - 1 reports

Pharmacokinetics and Drug Interaction Profile of Cobicistat-Boosted Elvitegravir with Carbamazepine

ICAAC 2014 54th Interscience Conferenceon Antimicrobial Agents and ChemotherapySeptember 5-9, 2014, Washington, DC Reported by Jules LevinICAAC - 54th Interscience Conference on Antimicrobial Agents and Chemotherapy September 5-9, 2014 Washingtion DC, ... [Published National AIDS Treatment Advocacy Project - Sep 11 2014]
First reported Sep 09 2014 - Updated Sep 09 2014 - 1 reports

Gilead's monopoly in HIV therapies to be toppled by Viiv's Triumeq; report09-09-2014

The recent US Food and Drug Administration and European Commission approval of HIV specialist ViiV Healthcare’s Triumeq (dolutegravir/abacavir/lamivudine) will mean an end for Gilead Bioscience’s (Nasdaq: GILD)monopoly on the market, according to consultancy ... [Published Pharma Letter - Sep 09 2014]
First reported Sep 05 2014 - Updated Sep 05 2014 - 1 reports

Data on HIV/AIDS Discussed by Researchers at GlaxoSmithKline (Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or...

Data on HIV/AIDS Discussed by Researchers at GlaxoSmithKline (Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study)By a News Reporter-Staff News Editor ... [Published 4 Traders - Sep 05 2014]
First reported Sep 04 2014 - Updated Sep 04 2014 - 1 reports

Market Update (NASDAQ:GILD): Gilead Sciences to Present at Two Upcoming Investor Conferences in September

[Business Wire] – Gilead Sciences, Inc. today announced that its corporate presentation will be webcast from two upcoming investor conferences: the Robert W. Baird & Co. 2014 Heal Read more on this.. . . → Read More: Similar Articles: Gilead Sciences ... [Published Stock Nod - Sep 04 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

Tenofovir and NSAIDs

Cases of acute renal failure after initiation of high dose or multiple non-steroidal anti-inflammatory  drugs have been reported in patients treated with tenofovir disoproxil fumarate and with  risk factors for renal dysfunction. In patients at risk for ... [Published Pharmaceutical Journal - Aug 29 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Tenofovir Alafenamide Vs. Tenofovir Disoproxil Fumarate in Single Tablet Regimens for Initial HIV-1 Therapy: A Randomized Phase 2 Study

Objectives: To evaluate the safety and efficacy of the novel tenofovir prodrug, tenofovir alafenamide (TAF), as part of a single-tablet regimen (STR) for the initial treatment of HIV-1 infection.Design: Phase 2, randomized, double-blind, double-dummy, ... [Published JAIDS - Aug 13 2014]

Quotes

...The researchers proposed that this single-tablet regimen containing darunavir and TAF "offers a promising option for initial HIV treatment, with the high barrier to resistance of darunavir, and the potential for improved bone and renal safety with TAF."
The researchers concluded that Stribild is "an efficacious, durable, well-tolerated, and safe treatment regimen for HIV-1-infected, treatment-naive, black patients."
According to the news editors, the research concluded: "DTG 50 mg BID-based therapy was effective in this highly treatment-experienced population with INI-resistant virus."

More Content

All (29) | News (20) | Reports (0) | Blogs (9) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
ICAAC 2014: Cobicistat Long-term Efficacy Match... [Published HIV and Hepatitis.com - Sep 16 2014]
Subgroup Analysis of Response to Stribild vs At... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
First Single-Tablet PI Regimen With Darunavir a... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
Similar 144-Week Results With Cobicistat or Rit... [Published National AIDS Treatment Advocacy Project - Sep 16 2014]
Switch From RTV to COBI To Boost a PI With Mode... [Published National AIDS Treatment Advocacy Project - Sep 12 2014]
FDA Updates Stribild Labeling [Published AIDSinfo At-a-Glance: Offering Information on H ... - Sep 12 2014]
Stribild Advantages vs Atripla in Blacks Throug... [Published National AIDS Treatment Advocacy Project - Sep 12 2014]
Pharmacokinetics and Drug Interaction Profile o... [Published National AIDS Treatment Advocacy Project - Sep 11 2014]
Gilead's monopoly in HIV therapies to be topple... [Published Pharma Letter - Sep 09 2014]
Data on HIV/AIDS Discussed by Researchers at Gl... [Published 4 Traders - Sep 05 2014]
Market Update (NASDAQ:GILD): Gilead Sciences to... [Published Stock Nod - Sep 04 2014]
Tenofovir and NSAIDs [Published Pharmaceutical Journal - Aug 29 2014]
ViiV bags US approval for HIV blockbuster-in-wa... [Published PMLive - Aug 26 2014]
The Role of Triumeq in HIV Treatment [Published The Body - Aug 26 2014]
Nonoccupational Postexposure Prophylaxis for HI... [Published General Medicine eJournal - Aug 18 2014]
Why Gilead Is The Most Exciting Growth Opportun... [Published Seeking Alpha - Aug 15 2014]
Tenofovir Alafenamide Vs. Tenofovir Disoproxil ... [Published JAIDS - Aug 13 2014]
Lauren Rudd: Merck, naysayers have yet to destr... [Published Northwestern - Jun 15 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 15 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 15 2014]
US FDA accepts Gilead’s NDA for cobicistat & el... [Published PharmaBiz - Apr 23 2014]
A Second Company Asks FDA to Reconsider Denial ... [Published FDA Law Blog - Apr 22 2014]
Gilead Sciences’ New Drug Applications for Cobi... [Published Business Wire Health News - Apr 21 2014]
FDA is Asked to Reconsider Denial of NCE Exclus... [Published FDA Law Blog - Apr 09 2014]
FDA Denies 3 Petitions Seeking NCE Exclusivity ... [Published FDA Law Blog - Feb 24 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Feb 20 2014]
Product Positioning 2.0 [Published Pharmaceutical Executive - Feb 05 2014]
Opinion/decision on a Paediatric Investigation ... [Published Opinion/decision on a Paediatric Investigation ... - Feb 04 2014]
Mylan named as Gilead's exclusive branded medic... [Published PharmaBiz - Jan 31 2014]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA Updates Stribild Labeling [Published AIDSinfo At-a-Glance: Offering Information on H ... - Sep 12 2014]
On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two ...
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 15 2014]
Human medicines European public assessment repo... [Published Pending EC decisions and European Public Assess ... - May 15 2014]
A Second Company Asks FDA to Reconsider Denial ... [Published FDA Law Blog - Apr 22 2014]
By Kurt R. Karst –The battle over New Chemical Entity (“NCE”) exclusivity for Fixed-Dose Combination (“FDC”) drugs continues to heat up.  In a recent Petition for Reconsideration and Petition for Stay (Docket No. FDA-2013-P-0119), Ferring Pharmaceuticals, ...
Gilead Sciences’ New Drug Applications for Cobi... [Published Business Wire Health News - Apr 21 2014]
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s refiling of two New Drug Applications (NDA) for cobicistat, a pharmacoenhancing or “boosting” ...
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.